Salas Maribel, Hughes Dyfrig, Zuluaga Alvaro, Vardeva Kawitha, Lebmeier Maximilian
Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL 35294-4410, USA.
Value Health. 2009 Sep;12(6):915-22. doi: 10.1111/j.1524-4733.2009.00539.x. Epub 2009 Apr 27.
Information on the health care costs associated with nonadherence to treatments for diabetes is both limited and inconsistent. We reviewed and critically appraised the literature to identify the main methodological issues that might explain differences among reports in the relationship of nonadherence and costs in patients with diabetes.
Two investigators reviewed Medline, EMBASE, Cochrane library and CINAHL and studies with information on costs by level of adherence in patients with diabetes published between January 1, 1997 and September 30th 2007 were included.
A total of 209 studies were identified and ten fulfilled the inclusion criteria. All included studies analyzed claims data and 70% were based on non-Medicaid and non-Medicare databases. Low medication possession ratios were associated with higher costs. Important differences were found in the ICD-9/ICD-9 CM codes used to identify patients and their diagnoses, data sources, analytic window period, definitions of adherence measures, skewness in cost data and associated statistical issues, adjustment of costs for inflation, adjustment for confounders, clinical outcomes and costs.
Important variation among cost estimates was evident, even within studies of the same population. Readers should be cautious when comparing estimated coefficients from various studies because methodological issues might explain differences in the results of costs of nonadherence in diabetes. This is particularly important when estimates are used as inputs to pharmacoeconomic models.
关于糖尿病治疗不依从相关医疗保健成本的信息有限且不一致。我们回顾并批判性地评估了文献,以确定可能解释糖尿病患者不依从与成本关系报告差异的主要方法学问题。
两名研究人员检索了Medline、EMBASE、Cochrane图书馆和CINAHL,并纳入了1997年1月1日至2007年9月30日期间发表的有关糖尿病患者依从性水平与成本信息的研究。
共识别出209项研究,其中10项符合纳入标准。所有纳入研究均分析了理赔数据,70%基于非医疗补助和非医疗保险数据库。低药物持有率与更高成本相关。在用于识别患者及其诊断的ICD - 9/ICD - 9 CM编码、数据来源、分析窗口期、依从性测量定义、成本数据的偏态及相关统计问题、成本的通胀调整、混杂因素调整、临床结局和成本方面发现了重要差异。
即使在同一人群的研究中,成本估计之间也存在明显差异。在比较不同研究的估计系数时,读者应谨慎,因为方法学问题可能解释糖尿病不依从成本结果的差异。当估计值用作药物经济学模型的输入时,这一点尤为重要。